Introduction
An ageing population is one of the main challenges faced by developed countries. Older people have a higher prevalence of ailments, diseases and chronic medical conditions that often result in simultaneous treatment with multiple drugs. They are known to be at increased risk of adverse drug effects compared to younger populations (1) . This is because they consume more drugs and do so over longer periods of time, thereby exponentially increasing the number of possible drug interactions. Furthermore, physiological changes occurring as a consequence of the ageing process alter drug pharmacokinetics and pharmacodynamics in the elderly compared to younger adults, disturbing absorption, distribution, metabolism and excretion processes (2) . Moreover, since this population group is generally excluded from clinical trials, drug administration to the elderly is frequently guided by data from studies of younger people without comorbidities (3) .
Numerous studies have been published about potentially inappropriate drug use in the elderly population (4, 5) , with concerns about the consequences increasing in recent years. Several instruments, criteria and algorithms have been developed to enable more rational and appropriate use of medication in elderly patients. The most widely used include Beers Criteria (6) , Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert Doctors to Right Treatment (STOPP/START) (7), Improving Prescribing in the Elderly Tool (IPET) (8) , Assessing Care of Vulnerable Elderly (ACOVE) (9) and Medication Appropriateness Index (MAI) (10) . Another tool is the Good Palliative-Geriatric Practice (GP-GP) algorithm (11) , which has shown to be effective and safe for institutionalized elderly people in nursing homes (12) . There is growing evidence about the safety and effectiveness of interventions using these tools, but results from randomized clinical trials are controversial (13) . Although improvements in drug appropriateness and reduction in number of medications have been reported (13, 14) , limited evidence exists regarding clinically relevant improvements, such as unplanned hospital admissions, and regarding their economical impact (15) . There is a special gap of clinical trials assessing the impact of primary care pharmacist interventions using the mentioned tools in terms of emergency visits, hospitals admissions and quality of life. The objective of this study was to assess the effectiveness and safety of implementing a medication evaluation programme for polymedicated (8 or more drugs) elderly persons living in the community.
Materials and methods

Design and study population
A randomized, open-label, multicentre, parallel-arm clinical trial was conducted with a study population composed of communitydwelling elderly people (non-institutionalized) aged 70 years and older, receiving 8 or more drugs and resident in the municipalities of Mataró and Argentona (Barcelona, Spain). The study included all 7 Primary Health Care Centres in Mataró and Argentona (122 905 and 11 718 inhabitants, respectively, with 13 290 and 1194 aged 70 years and over, respectively). Recruitment took place between February and May 2012. Considered eligible were all patients aged 70 years and older prescribed 8 or more medications (except ointments administered topically) who gave their informed consent in writing to participate in the study. Exclusion criteria were patients with an estimated life expectancy of less than 6 months, patients with active cancer, nursing home residents and persons participating in another drug evaluation clinical trial or programme for the elderly population. The study subjects were pre-selected from the primary care databases. Randomly selected from among this set of patients were 10 patients per 54 family physicians (total 540). A recruitment visit was arranged by telephone in which a nurse confirmed that patients met all selection criteria, informed them about the study and obtained their written consent. The study protocol was approved by the Clinical Research Ethics Committee (CEIC 05/12) before recruitment. Of the 540 pre-selected patients, 37 were rejected as not meeting the selection criteria, leaving 503 patients who were blindly randomized to one or other of the two study arms. Each family physician received 10 sealed, opaque envelopes with identification numbers (assigned consecutively in strict chronological order of recruitment) on the back. Each envelope contained a card with the same identification number and the intervention group to which the subject was assigned. One-to-one assignment was based on a list of random numbers generated by a statistical program. Envelops were not prepared in primary care centres but in the research unit.
Study intervention
The intervention consisted of 3 consecutive phases. First, a trained and experienced clinical pharmacist evaluated all drugs prescribed to each patient using the GP-GP algorithm and basing their decision about appropriateness on the STOPP/START criteria. Second, the pharmacist discussed recommendations for each drug with the patient's physician in order to come up with a final set of recommendations. Drug assessment was conducted in all cases by the same clinical pharmacist (IG). Finally, these recommendations were discussed with the patient, and a final decision was agreed by physicians and their patients in a face-to-face visit. All changes in prescribed medication were registered in the electronic clinical notes and in the study's record form. The goal of the study intervention was to improve current prescription medication in community-dwelling elderly persons in our setting and so improve routine clinical practice. Thus, control group patients followed the usual treatments and control procedures of their physicians.
Main outcome measures
Indicators of drug appropriateness were as follows: (i) the percentage of patients with at least 1 recommendation; (ii) percentage of patients with at least 1 treatment change, namely, discontinuation, substitution with a more cost-effective alternative, dose adjustment or a new drug prescription; (iii) the mean number of drugs per patient with recommendations and (iv) the mean number of drugs per patient with changes implemented. Main outcome measures regarding intervention effectiveness were as follows: (i) number of medications prescribed at 3, 6 and 12 months; (ii) treatment restart ratio (after discontinuation); (iii) primary care and emergency department consultation rate for acute conditions; (iv) hospitalization rate; (v) mortality rate; (vi) baseline, 3-month and 6-month self-reported quality of life (measured using EuroQoL-5D, www. euroqol.org) and (vii) baseline, 3-month and 6-month treatment adherence (measured using the Morisky-Green test). Electronic primary care clinical histories were the main information source for patients, including for medication (prescribed drugs were understood to be the medication featuring in the patients' histories). Other study information (EuroQoL-5D, Morisky-Green) was obtained directly from the patient. One-year follow-up was considered sufficient to assess the impact of the implemented recommendations and to assess possible adverse effects. A safety check was conducted after the first month in the intervention group and follow-up checks to assess outcomes were conducted at 3, 6 and 12 months in both study groups.
Statistical analysis
To estimate sample size, the main outcome variable was considered to be the number of drugs prescribed to the patient after 6 months. For an alpha risk of 0.05 and a beta risk of 0.1 (two-tailed test), it was estimated that 254 patients would be needed per group (508 in total) to detect a statistically significant average between-group difference of 1.25 drugs, assuming a standard deviation (SD) of 4% and 15% loss to follow-up at 6 months. All data were recorded in an electronic database for debugging purposes and subsequent statistical analysis. The main patient characteristics were descriptively analysed using means and SD for quantitative variables and percentages for qualitative variables. Drug suitability was analysed in terms of "recommendations" regarding potentially inappropriate drugs and drug changes implemented. Recommendations and changes were expressed as percentages of the total of prescribed drugs and also as averages per patient. Intervention effectiveness was evaluated using an intention-to-treat (ITT) analysis. For the two groups, continuous variables were compared using the Student-t or Mann-Whitney U test and categorical variables were compared using the chi-square test or Fisher's exact test. In the analysis of efficacy Bonferroni correction was applied. As 5 main outcome measures of efficacy were considered, statistical significance was set at 0.01.
Results
Sample description
A total of 503 patients participated in the study, 252 randomized to the intervention group and 251 to the control group. Two hundred forty two patients in the intervention group and 246 patients in the control group were followed for 12 months (see Figure 1 ). At baseline, no differences were observed between groups in age, sex, educational level and family support. Both groups were also similar in terms chronic illnesses, with no differences between groups except for depression, which was more common in the intervention group. The most common comorbidities were hypertension, osteoarthritis, dyslipidaemia, heart disease/failure, diabetes and depression (see Table 1 ). Before intervention, mean (SD) number of drugs prescribed per patient were 10.8 (2.52) in the intervention group and 10.9 (2.65) in the control group (P = 0.912).
Drug appropriateness
For the total of 2709 prescribed drugs evaluated for the intervention group (252 patients), the clinical pharmacist made recommendations in 718 (26.5%) of cases. After discussion with the patients' physicians, 581 changes were implemented, meaning that 21.4% of all prescriptions were rated as potentially inappropriate, with the clinical pharmacist's recommendations accepted in 80.9% of the cases. Table 2 classification. Table 2 also shows, for each therapeutic drug group, the number of prescribed drugs, recommendations and changes and also the recommendation acceptance rates. Gastric protectors, antipsychotics and benzodiazepines were the most potentially inappropriate drug categories.
Intervention effectiveness
Just after the intervention, the number of drugs prescribed to intervention group subjects was reduced to a mean of 10.03 medications/patient, significantly lower than the control group value of 10.91 (P = 0.001). Table 3 shows comparisons between the two groups, at 3, 6 and 12 months, regarding the percentage of patients with at least one medication discontinued, dose adjusted or substituted and regarding the mean number of drugs discontinued, dose adjusted or substituted per patient. Significant differences were observed between groups in all these outcome measures. Also recorded were the number of intervention group-restarted drugs at 3, 6 and 12 months (12.0%, 15.9% and 17.3%, respectively). Control group-restarted drugs were 5.7% and 11.3% at 6 and 12 months, respectively; restarts at 3 months could not be calculated as there were no baseline discontinuations. As for new prescriptions, no differences were observed at 3, 6 and 12 months between the control group (120, 78 and 208 prescriptions, respectively) and intervention groups (135, 62 and 209 prescriptions, respectively). Morisky-Green test results indicated improved treatment adherence in the intervention group. While no significant differences were observed between the two groups in initial treatment adherence (61.8% in the intervention group versus 60.2% in the control group; P = 0.713), at 6 months adherence was higher in the intervention group (76.4% versus 64.1%; P = 0.005). The intervention made no difference in self-reported quality of life according to EuroQoL-5D, which, at 6 months, remained largely stable in both groups, with a change from the baseline score (on a scale of 0-100) of −2.09 points in the intervention group and of 0.67 points in the control group (P = 0.324). Table 4 compares health care resource use by the two groups at 3-, 6-and 12-month follow-up. Significant differences were observed in the number of primary care visits at 3 and 6 months but not at 12 months; no significant differences were observed in any follow-up controls in relation to emergency department visits, consultations with specialists or additional tests.
Intervention safety
No differences were found between the control and intervention groups in terms of mortality and hospitalizations rates during the entire follow-up period (Table 4) . Causes of death and medication changes for the 7 intervention group patients who died were as follows: (i) pancreatic cancer: acetylsalicylic acid dose adjustment and potassium clorazepate substitution with lorazepam; (ii) sepsis: losartan discontinuation, enalapril dose adjustment and glibenclamide substitution with gliclazide; (iii) respiratory infection: omeprazole discontinuation; (iv) heart failure: tamsulosin and solifenacin discontinuation and new paracetamol prescription; (v) heart failure: repaglinide and bisoprolol dose adjustment and new citalopram and furosemide prescription; (vi) myocardial infarction: pregabalin dose adjustment and (vii) diarrhoea and dehydration in a 96-year-old frail women: glyceryl trinitrate and diazepam discontinuation and prednisone dose adjustment. Recommendations regarding drug discontinuation, dose adjustment or drug substitution.
Discussion
Our study indicated that over a quarter (26.5%) of prescriptions to polymedicated community-dwelling elderly people were potentially inappropriate. The study intervention generated a change to improve prescription in 21.4% of total drugs prescribed, representing a mean of 2.07 medication changes per patient. Of the initially prescribed drugs in the intervention group, 9.1% were discontinued, 3.2% were substituted with more cost-effective alternatives, 6.9%
were dose adjusted and 2.2% were new prescriptions. At 6-month follow-up, discontinuations and new prescriptions resulted in a 5% drug reduction in the intervention group, with no risk to health and no increase in hospitalization or death rates. Our results would corroborate the hypothesis that potentially inappropriate medication of community-dwelling elderly people is highly prevalent. There is growing recognition of drug inappropriateness as a public health problem, given its potential impact on morbidity, mortality and health care resource use (16) . A systematic review points to prevalence ranging between 11.5% and 62.5% for potentially inappropriate medication, defined as the proportion of patients with at least one potentially inappropriate prescription (17) , with the rates varying depending on the criteria used, the study population and the country. Our rate of 95.6% is higher than in other studies, probably due to study population differences: our study only included elderly people taking 8 or more different drugs. Polypharmacy is known to be associated with a higher probability of both inappropriateness and adverse effects (17) . Some studies have estimated that approximately 6-7% of hospital admissions of the elderly are due to drug-related problems and that about 60% of such admissions could be avoided if drug prescriptions were appropriate (18) . A clear opportunity exists to improve drug prescriptions in the elderly population, most especially among polymedicated patients, for whom drug prescription criteria and recommendations based on the best scientific evidence are needed. Programmes to change prescribing patterns also need to be developed, based on training health care professionals, disseminating and implementing both appropriate prescribing criteria and agreed lists of unsuitable drugs for the elderly population. As reported by other authors, intervention in the present study improved medication appropriateness for the elderly population, resulting in actual changes of 21.4% with respect to all the evaluated drugs and of 80.9% with respect to recommendations regarding potentially inappropriate prescriptions. In a German study with 63 community-dwelling elderly people, the implementation of an adapted GP-GP algorithm resulted in 13% and 9% of drugs being changed and discontinued, respectively, and a recommendations acceptance rate of 75% (19) . Another non-randomized study conducted in nursing homes and based on the GP-GP algorithm showed a mean drug reduction of 2.8 drugs per patient, with no significant adverse effects or increased health care resource use (12) . A non-controlled Israeli study of 70 community-dwelling elderly people that used the same algorithm resulted in recommendations to discontinue 58% of prescribed drugs, a reduction of 46% in medications (4.2 per patient on average) and a recommendations acceptance rate of 81% (11) . Differences in socio-cultural context and health care organization in different countries may influence prescribing habits and explain between-country differences regarding potentially inappropriate medication rates and intervention effects. Our intervention led to no differences in emergency department consultations and in hospitalizations or mortality. These results suggest that, despite the reduction in the number of prescriptions, the study intervention was safe. However, they also indicate no effect of the study intervention in improving such relevant clinical outcomes. The translation of potentially drug appropriateness into a reduction in hospital visits and admissions may require a more sustained intervention over time, a larger follow-up period and a larger sample size, since the incidence of drug-related problems that require hospitalization is relatively small. Regarding the number of primary care visits, the intervention group had an extra visit in which medication changes were explained and agreed. Cost of study intervention deriver mainly from pharmacist and physician time and the additional visit to primary care. On the other hand, direct savings deriver mainly from discontinued drugs, dose adjustments and drug substitutions by more cost/effective ones. At 6 months of followup, study intervention resulted in a mean drug reduction of 0.85 drugs/patient. Whether the intervention is a cost saving alternative will largely depend on context parameters such as drug prices or fees of health professionals. Unlike the present study, Garfinkel and co-workers noted a significant decrease in both mortality and the annual admissions rate in the intervention compared to the control group (12) . Our study revealed no effect of the intervention on mortality, while showing that the deaths that occurred in the intervention group were unrelated to the changes in medication. Other clinical trials showed an effect of medication assessments by a pharmacist with a significant reduction in drug-related problems and negative outcomes associated with medication such as falls (14) . However, the evidence of the impact of pharmacists' interventions on health outcomes, quality of life or cost/effectiveness of care is controversial. A systematic review of 20 randomized controlled trials (16 of which focused on older people) demonstrates a lack of evidence to suggest that pharmacist interventions have a benefit on the reduction of unplanned hospital admissions in the older population (15) . Primary outcome of this review was unplanned admissions and did not take into account other outcomes such as medication-related problems, adherence, quality of life and mortality, which have been evaluated in other systematic reviews, concluding that the addition of clinical pharmacist services in the care of inpatients generally resulted in improved care, with no evidence of harm (20) .
The present study has some limitations. First of all, the results were not evaluated blind; however, we are of the opinion that the main outcome measures were not affected, namely, the number of prescribed drugs, consultations, hospitalizations and deaths. A second limitation is possible intervention-to-control contagion, given that the prescribing physicians who received recommendations from the pharmacist regarding intervention group patients also had patients in the control group. The control group could thus have indirectly benefited from the intervention, thereby diluting-but not increasing-the effect of the intervention study. Thirdly, sample size was estimated for the main outcome measure, but the study has limited statistical power for secondary endpoints such as safety measures. Finally, the lack of periodic intervention reminders can be considered a shortcoming in the study intervention design.
Conclusion
In summary, evaluation of medication prescribed to communitydwelling elderly people by a clinical pharmacist using the GP-GP and STOPP/START tools proved to be effective in reducing the number of prescribed drugs and in improving drug appropriateness and treatment adherence in our setting. The intervention, which was well received by both physicians and patients, proved to be safe and led to no hospitalizations or deaths but, apart from saving drugs, did not demonstrate a reduction in health care resource consumption.
